# dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma

> **NCT06609863** · NA · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 27 (estimated)

## Conditions studied

- Advanced Hepatocellular Carcinoma
- Atezolizumab
- Bevacizumab
- Chemotherapy

## Interventions

- **PROCEDURE:** dTACE-HAIC

## Key facts

- **NCT ID:** NCT06609863
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-01
- **Primary completion:** 2025-10-01
- **Final completion:** 2026-06-30
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2024-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06609863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06609863, "dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06609863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*